Today we are talking to Ram Aiyer. Ram is CEO of Korro Bio, an RNA base editing company focused on co-opting ADAR, a naturally present editing system in all our cells to base edit A to I (which is translated as a G) in RNA. Prior to Korro, Ram was CBO and CFO of Corvidia, a company he successfully helped build and sell to Novo Nordisk for 2.1Bn$. Prior to Corvidia he was an EIR at BioHealth Innovation. He started his scientific career at Janssen Pharmaceuticals and held leadership roles at FlowMetric, Sofinnova Partners, and JP Morgan Chase.

Today we discuss his path to becoming the CEO of a biotech company, the transition for a first time CEO, his success at Corvidia, running a leading biotech company in today’s markets and the science/technology & culture underpinning Korro.